By David Adamson, MD, Founder & CEO, ARC Fertility
Artificial Intelligence (AI) has the potential to reshape fertility care by enhancing diagnostics, optimizing treatments and expanding access. However, addressing algorithmic bias and regulatory oversight is crucial for equitable implementation. As employers adopt AI-assisted fertility benefits, reproductive care can become more inclusive and affordable.
Embracing Artificial Intelligence in Fertility Treatment
Artificial Intelligence (AI) has the potential to redefine reproductive medicine by enhancing diagnostic accuracy, optimizing fertility treatments and increasing overall success rates[i]. By integrating machine learning algorithms, predictive analytics and real-time patient monitoring, AI can enable more personalized and efficient fertility care[ii]. The significance and impact of AI on reproductive care is just beginning to be implemented in clinical care.
One of AI’s key strengths in fertility care is predictive modeling, which processes hormonal fluctuations, ovarian reserve markers (AMH, FSH), genetic predispositions and previous assisted reproductive technology (ART) cycle outcomes to refine treatment plans[iii]. These data-driven insights can allow clinicians to tailor medication dosages, ovarian stimulation strategies and embryo transfer timing, ultimately reducing treatment cycles and improving implantation success[iv].
Beyond its direct clinical applications, AI is being used to streamline fertility clinic management. AI-assisted appointment scheduling, medication adherence tracking and automated cycle monitoring can optimize patient care workflows, reduce inefficiencies and ensure critical procedures such as egg retrieval and embryo transfer occur at precisely timed intervals[v].
While AI’s capabilities continue to evolve, maintaining regulatory oversight, ensuring ethical application and fostering clinician involvement are crucial to preserving patient trust, equity and long-term effectiveness in fertility care[vi].
AI-DRIVEN EMBRYO IMAGING, SELECTION AND SPERM ANALYSIS
AI in Embryo Selection and Non-Invasive Grading
Historically, embryo selection relied on subjective manual grading, which results in variability in quality of embryos selected and implantation rates[vii]. AI-driven embryo selection can eliminate variability by analyzing thousands of embryonic images to predict viability based on cell division timing, fragmentation levels and blastocyst expansion. As AI-powered embryo grading improves, it can potentially increase implantation success rates and reduce failed transfers by prioritizing embryos with the highest developmental potential[viii].
AI-integrated time-lapse imaging further enhances embryo selection by continuously tracking developmental progress, providing a real-time assessment rather than relying on fixed observation time points. By applying morphokinetic analysis, AI identifies subtle developmental patterns that embryologists may miss, ensuring the best-quality embryos are selected for implantation or cryopreservation.
AI in Sperm Selection for ART
AI also can play a critical role in sperm selection, particularly in male factor infertility cases, where traditional manual methods struggle to assess sperm quality comprehensively. AI-driven computer-assisted sperm analysis (CASA) systems evaluate sperm motility, morphology and DNA fragmentation, potentially improving the selection of the healthiest sperm for ART procedures such as intracytoplasmic sperm injection (ICSI)[ix].
Additionally, microfluidic AI-assisted sperm sorting mimics natural sperm selection processes, improving the isolation of high-motility, genetically stable sperm, potentially optimizing fertilization outcomes and enhancing embryo quality.
EXPANDING ACCESS TO FERTILITY CARE WITH AI
AI can expand access to fertility care, particularly for patients in remote or underserved regions. AI-powered telemedicine platforms now provide virtual fertility consultations, remote treatment monitoring and AI-assisted reproductive health assessments, reducing the need for frequent in-clinic visits and lowering the overall cost of care[x].
Additionally, AI-driven mobile applications offer cycle tracking, ovulation prediction and reproductive health monitoring, allowing individuals to make informed family-planning decisions before seeking medical intervention. These digital tools help patients monitor hormonal fluctuations, track menstrual cycles and receive AI-generated fertility recommendations tailored to their specific biological patterns.
Employers are increasingly incorporating AI-assisted fertility benefits into corporate health plans, improving financial accessibility to ART and reducing cost burdens on employees seeking reproductive assistance[xi]. AI-powered telehealth consultations, predictive fertility diagnostics and financial reimbursement programs are helping employees access personalized, data-driven fertility care while minimizing economic barriers.
Personalized Fertility Treatment with AI-Driven Predictive Modeling
AI is revolutionizing fertility treatment personalization, using machine learning models to optimize cycle monitoring, ovulation prediction and ovarian stimulation[xii]. These models analyze hormonal levels, follicular growth rates and endometrial receptivity markers to fine-tune medication dosages, ovulation timing and embryo transfer scheduling.
Additionally, AI-enhanced ovarian stimulation protocols can help reduce the risk of ovarian hyperstimulation syndrome (OHSS) by dynamically adjusting gonadotropin dosages based on real-time hormonal fluctuations. AI-driven uterine receptivity assessments can potentially also improve implantation success rates by pinpointing the most favorable endometrial conditions for embryo transfer.
AI in Patient Engagement and Support
AI is improving patient engagement and adherence through digital platforms, which enhance education, streamline consultations and support long-term monitoring. These AI-driven tools use interactive features to improve understanding, reduce stress and promote adherence to treatment protocols[xiii].
AI-powered Natural Language Processing (NLP) systems interpret complex medical records, translating them into patient-friendly insights to enhance health literacy and treatment understanding[xiv]. AI-driven fertility support platforms also connect patients with peer networks and mental health resources, addressing emotional challenges associated with infertility treatments.
ETHICAL CONSIDERATIONS AND BEST PRACTICES FOR AI IMPLEMENTATION
Addressing Bias and Ethical Concerns in AI
AI is revolutionizing fertility care, improving diagnostic precision and personalized treatment. However, ethical concerns persist, particularly regarding algorithmic bias, data inclusivity and equitable access. AI models trained on non-diverse datasets may exacerbate disparities in reproductive healthcare[xv].
Bias in AI-driven fertility predictions can distort success rates for underrepresented groups, including racial minorities, LGBTQ+ individuals and patients with reproductive conditions like PCOS or endometriosis. AI-based ovulation tracking and ART decision-support tools may also be less effective for individuals with irregular cycles or gender-affirming fertility care needs.
To mitigate bias, AI developers must expand training datasets and conduct regular audits to ensure demographic inclusivity. AI models should undergo continuous recalibration to maintain accuracy (4). Additionally, Explainable AI (XAI) should be prioritized to ensure transparency in decision-making and regulatory compliance[xvi].
Transparency, Explainability and Trust in AI
Many AI systems operate as “black boxes,” making it difficult for clinicians and patients to understand how recommendations are formulated. This lack of transparency can erode trust, create regulatory challenges and increase clinician hesitancy in AI adoption[xvii].
Deep-learning models identify statistical correlations rather than follow explicit medical rules, raising concerns about whether AI fertility predictions align with evidence-based practices[xviii]. Regulatory agencies require AI explainability to ensure safe, ethical deployment.
To enhance transparency, AI should incorporate rule-based models alongside deep learning, providing interpretable and auditable fertility predictions. Feature attribution techniques should also be used to clarify how clinical factors like hormonal levels, embryo grading and patient age influence AI-driven recommendations.
Clinician oversight remains critical in AI-assisted reproductive care. AI should function as a decision-support tool rather than an autonomous authority, allowing specialists to review and override AI-generated recommendations when necessary.
For patients, AI-driven fertility platforms should provide clear, accessible explanations of AI-generated insights, reducing uncertainty and improving adherence to treatment plans . Educational tools, non-technical summaries and visual aids can empower patients to make informed decisions about their reproductive health.
Regulatory Oversight and Compliance in AI-Based Fertility Care
As AI advances, robust regulatory oversight is necessary to ensure safety, accuracy and ethical compliance. Unlike traditional medical interventions, AI models evolve over time, requiring ongoing regulatory updates to maintain effectiveness[xix].
Regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) classify AI-powered fertility tools as high-risk medical devices, requiring thorough validation studies before clinical approval[xx]. One key challenge is model drift, where AI performance declines over time due to shifting patient demographics, clinical protocols or new medical data. To prevent this, regulatory agencies mandate post-market surveillance and periodic model retraining.
Ethical compliance and data privacy are equally critical. AI-driven reproductive technologies must adhere to global privacy laws, such as General Data Protection Regulation (GDPR),
Europe, and Health Insurance Portability and Accountability Act (HIPAA), U.S., ensuring secure handling of patient data. Regulatory frameworks should enforce ethical AI governance policies to preserve trust, safety and equity in fertility care[xxi].
THE ROLE OF EMPLOYERS IN ADVANCING FERTILITY CARE
As fertility challenges become more prevalent, employers are increasingly recognizing the importance of reproductive healthcare as part of their employee benefits packages. The integration of AI-assisted fertility solutions into employer-sponsored health plans is expanding access to ART, reducing financial burdens and improving workforce well-being[xxii].
By investing in AI-powered fertility benefits, companies foster inclusivity, attract top talent and enhance employee retention.
Employer-Sponsored AI-Assisted Fertility Benefits
Fertility treatments can be financially burdensome, with in vitro fertilization (IVF) cycles costing between $12,000 and $25,000 per attempt, not including medication expenses[xxiii]. Despite increasing demand for fertility care, many traditional employer health plans offer limited coverage, leaving employees to shoulder significant out-of-pocket costs.
To address this gap, more employers are incorporating AI-powered fertility solutions into their benefits programs to help make treatments more efficient, accessible and personalized. AI-driven fertility diagnostics can enable early detection of reproductive health issues, allowing employees to seek treatment before conditions escalate.
AI-assisted embryo selection enhances IVF outcomes by optimizing embryo viability, increasing implantation success and reducing failed transfers, ultimately minimizing treatment cycles and lowering costs. Additionally, AI-enhanced telemedicine fertility consultations provide virtual assessments, breaking down geographical barriers and improving access to specialist care, particularly for those in remote or underserved areas.
By integrating AI-assisted fertility benefits, employers demonstrate a commitment to employee well-being and healthcare inclusivity. These offerings help ensure that family-building support is accessible to all employees, including LGBTQ+ individuals and single parents by choice, fostering a more inclusive and supportive workplace.
The Business Case for Fertility Benefits
Fertility benefits have transitioned from a niche perk to a competitive advantage for companies aiming to attract and retain top talent. Organizations that offer comprehensive fertility coverage, including AI-enhanced ART treatments, experience higher employee satisfaction and loyalty.
Fertility challenges can significantly impact workplace performance, leading to increased absenteeism as employees navigate medical appointments, hormone therapy and recovery periods. The emotional toll of infertility and unsuccessful ART cycles can contribute to burnout, decreased engagement and job dissatisfaction. AI-driven fertility support programs, such as virtual coaching and psychological counseling, can help employees manage stress while maintaining productivity.
Providing AI-powered reproductive healthcare also strengthens workforce retention. Employees are more likely to remain with companies that support their family-building goals, with studies showing that 57% would switch jobs for fertility coverage[xxiv]. By integrating AI-assisted fertility benefits, employers create a supportive work environment that enhances morale, reduces turnover and improves overall workplace productivity.
Expanding Employer-Sponsored AI Fertility Benefits
Employers are enhancing their fertility benefits by integrating AI-powered reproductive healthcare solutions, ensuring greater accessibility and inclusivity. This expansion covers AI-driven fertility treatments, financial assistance programs, virtual fertility coaching and partnerships with AI-enabled fertility clinics.
AI-powered fertility treatments are now included in many employer-sponsored plans, offering advanced technologies such as AI-driven embryo grading and selection to improve IVF success rates while reducing treatment cycles and costs.
To alleviate financial burdens, employers are introducing fertility grants and flexible spending accounts (FSAs) or health savings accounts (HSAs), allowing employees to allocate pre-tax dollars toward fertility treatments and AI-enhanced reproductive care.
Virtual fertility coaching is becoming a valued component of corporate wellness programs. AI-driven chatbots and virtual assistants provide personalized fertility guidance, while employees gain access to reproductive health specialists for preconception planning and fertility assessments. Educational workshops and webinars further support informed decision-making.
Additionally, employers are forming partnerships with AI-enabled fertility clinics and telemedicine providers to expand employee access to advanced reproductive care. These collaborations offer AI-driven telehealth fertility consultations, employer-negotiated discounts on IVF cycles and embryo freezing and comprehensive ART services that leverage AI-assisted diagnostics and predictive fertility modeling.
By embracing AI-assisted fertility solutions, employers not only enhance healthcare accessibility but also demonstrate a long-term commitment to employee well-being, inclusivity and work-life balance.
ADVANCING FERTILITY CARE THROUGH AI
AI is transforming reproductive medicine, enhancing treatment planning, embryo selection and fertility monitoring with unprecedented precision. AI-driven technologies are refining ART by analyzing large-scale clinical datasets, improving success rates and optimizing patient experiences .
However, realizing AI’s full potential in fertility care requires responsible integration, ethical oversight and cross-sector collaboration among clinicians, researchers, policymakers and employers.
As AI evolves, it is expected to further personalize fertility treatments, improving predictive modeling, diagnostic accuracy and patient outcomes. By enhancing treatment precision and reducing inefficiencies, AI can lower costs and make ART more accessible to a broader population. AI adoption in clinical care requires rigorous validation and continuous monitoring to ensure its effectiveness across diverse patient populations.
Employers also play a critical role in expanding access to AI-powered fertility treatments. Companies offering AI-assisted reproductive benefits must prioritize equitable access to ART to support diverse family-building needs, including LGBTQ+ individuals, single parents by choice and employees facing medical infertility. By integrating AI-powered fertility solutions into workplace benefits, employers can help mitigate financial burdens, improve workforce well-being and foster inclusivity.Maximizing AI’s impact in reproductive medicine demands multidisciplinary collaboration among healthcare providers, AI experts, industry leaders, employers and regulatory bodies. Through coordinated efforts, AI will continue to drive innovation, accessibility and efficiency in fertility care while maintaining safety, transparency and ethical integrity.
This article originally appeared in the July/August 2025 issue of Journal of Compensation and Benefits.
Notes:
[i] ScienceDirect, Artificial intelligence in in-vitro fertilization (IVF): A new era of precision and personalization in fertility treatments, David B. Olawade, Jennifer Teke, Khadijat K. Adeleye, Kusal Weerasinghe, Momudat Maidoki, Aanuoluwapo Clement David-Olawade, 2024, accessed on 2/26/25 at sciencedirect.com/science/article/pii/S246878472400182X.
[ii] ScienceDirect, The Exciting Potential for ChatGPT in Obstetrics and Gynecology, Amos Grünebaum, MD; Joseph Chervenak, MD, MBA; Susan L. Pollet, Esq; Adi Katz, MD; Frank A. Chervenak, MD, MMM,06/2023, accessed 2/26/25 on at sciencedirect.com/science/article/abs/pii/S0002937823001540
[iii] ScienceDirect, Deep Learning for Embryo Evaluation Using Time-Lapse: A Systematic Review of Diagnostic Test Accuracy, Aya Berman, MD; Roi Anteby, MD, MPH; Oriy Efros, MD, MHA; Eyal Kiang, MD; Shelly Soffer, MD, 2023, accessed on 2/26/25 at sciencedirect.com/science/article/abs/pii/S0002937823002648.
[iv] ScienceDirect, Artificial intelligence in in-vitro fertilization (IVF): A new era of precision and personalization in fertility treatments, David B. Olawade, Jennifer Teke, Khadijat K. Adeleye, Kusal Weerasinghe, Momudat Maidoki, Aanuoluwapo Clement David-Olawade, 2024, accessed on 2/26/25 at sciencedirect.com/science/article/pii/S246878472400182X.
[v] ScienceDirect, Artificial intelligence for sperm selection—a systematic review, Panagiotis Cherouveim, M.D., M.S., Constantine Velmahos, B.S., & Charles L. Bormann, Ph.D., 2024, accessed on 2/26/25 at sciencedirect.com/science/article/pii/S0015028223005332
[vi] JAMA Network, AI Developers Should Understand the Risks of Deploying Their Clinical Tools, MIT Expert Says, Samantha Anderer & Yulin Hswen, ScD, MPH, 2024, accessed on 2/26/25 at jamanetwork.com/journals/jama/fullarticle/2815046.
[vii] ScienceDirect, Deep Learning for Embryo Evaluation Using Time-Lapse: A Systematic Review of Diagnostic Test Accuracy, Aya Berman, MD; Roi Anteby, MD, MPH; Oriy Efros, MD, MHA; Eyal Kiang, MD; Shelly Soffer, MD, 2023, accessed on 2/26/25 at sciencedirect.com/science/article/abs/pii/S0002937823002648.
[viii] ScienceDirect, Artificial Intelligence for sperm selection—a systematic review. , Panagiotis Cherouveim, M.D., M.S., Constantine Velmahos, B.S., & Charles L. Bormann, Ph.D., 2024, accessed on 2/26/25 at sciencedirect.com/science/article/pii/S0015028223005332
[ix] ScienceDirect, , Artificial intelligence for sperm selection—a systematic review , Panagiotis Cherouveim, M.D., M.S., Constantine Velmahos, B.S., & Charles L. Bormann, Ph.D., 2024, accessed on 2/26/25 at sciencedirect.com/science/article/pii/S0015028223005332
[x] American Society for Reproductive Medicine (ASRM), Welcome to Tech Talk, 2024, accessed on 2/26/25 at asrm.org/news-and-events/asrm-news/latest-news/welcome-to-tech-talk/
[xi] American Journal of Managed Care (AJMC), The Evolving US Fertility Care Landscape: Strategies for Addressing Increasing Demand, 2024, accessed on 2/26/25 at ajmc.com/view/the-evolving-us-fertility-care-landscape-strategies-for-addressing-increasing-demand
[xii] ScienceDirect, Applications of artificial intelligence in ovarian stimulation: a tool for improving efficiency and outcomes. Eduardo Hariton, Zoran Pavlovic, Michael Fanton, Victoria S. Jiang. accessed on 2/26/25 at sciencedirect.com/science/article/pii/S0015028223005198
[xiii] Elsevier, Revolutionizing Urogynecology: Machine Learning Application with Patient-Centric Technology—Promise, Challenges, and Future Directions, Reut Rotem, Daniel Galvin, Yair Daykan, Yanlin Mi, Sabin Tabirca, & Barry A. O’Reilly, 2024, accessed on 2/26/25 at sciencedirect.com/science/article/abs/pii/S0301211524003440.
[xiv] Elsevier, Artificial Intelligence in Reproductive Medicine: Current Applications and Future Directions, William Rojas-Carabali, Rajdeep Agrawal, Laura Gutierrez-Sinisterra, Sally L. Baxter, Carlos Cifuentes-González, Yap Chun Wei, John Abisheganaden, Palvannan Kannapiran, Sunny Wong, Bernett Lee, Alejandra de-la-Torre, Rupesh Agrawal, Journal of Clinical and Translational Endocrinology, 2024, accessed on 2/26/25 at sciencedirect.com/science/article/pii/S2162098924000859.
[xv] JAMA Network, AI Developers Should Understand the Risks of Deploying Their Clinical Tools, MIT Expert Says, Samantha Anderer & Yulin Hswen, ScD, MPH, 2024, accessed on 2/26/25 at jamanetwork.com/journals/jama/fullarticle/2815046.
[xvi] JAMA Network, Recommendations to Ensure Safety of AI in Real-World Clinical Care, Dean F. Sittig, PhD & Hardeep Singh, MD, MPH, 2024, accessed on 2/26/25 at https://jamanetwork.com/journals/jama/fullarticle/2827434
[xvii] JAMA Network, AI Developers Should Understand the Risks of Deploying Their Clinical Tools, MIT Expert Says, Samantha Anderer & Yulin Hswen, ScD, MPH, 2024, accessed on 2/26/25 at jamanetwork.com/journals/jama/fullarticle/2815046.
[xviii] ScienceDirect, The Exciting Potential for ChatGPT in Obstetrics and Gynecology, Amos Grünebaum, MD; Joseph Chervenak, MD, MBA; Susan L. Pollet, Esq; Adi Katz, MD; Frank A. Chervenak, MD, MMM,06/2023, accessed 2/26/25 on at sciencedirect.com/science/article/abs/pii/S0002937823001540
[xix] JAMA Network, Recommendations to Ensure Safety of AI in Real-World Clinical Care, Dean F. Sittig, PhD & Hardeep Singh, MD, MPH, 2024, accessed on 2/26/25 at jamanetwork.com/journals/jama/fullarticle/2827434
[xx] U.S. Food and Drug Administration (FDA), Artificial Intelligence and Machine Learning (AI/ML) Software as a Medical Device, accessed on 2/26/25 at fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device.
[xxi] JAMA Network, Recommendations to Ensure Safety of AI in Real-World Clinical Care, Dean F. Sittig, PhD & Hardeep Singh, MD, MPH, 2024, accessed on 2/26/25 at jamanetwork.com/journals/jama/fullarticle/2827434
[xxii] SAGE Journals, Assisted Reproductive Technologies and Work, Employment and Society: Extending the Debate on Organisational Involvement in/Responsibilities around Fertility and Reproduction, Krystal Wilkinson, Clare Mumford, & Michael Carroll, Work, Employment and Society, Volume 37, Issue 5, accessed on 2/26/25 at journals.sagepub.com/doi/10.1177/09500170231155752.
[xxiii] White House, Fact Sheet: President Donald J. Trump Expands Access to In-Vitro Fertilization (IVF), 02/2025, accessed on 2/26/25 at whitehouse.gov/fact-sheets/2025/02/fact-sheet-president-donald-j-trump-expands-access-to-in-vitro-fertilization-ivf.
[xxiv] Maven Clinic, How Fertility & Maternity Benefits Tech is Transforming Workplace Support, 2024, accessed on 2/25/25 at mavenclinic.com/post/fertility-maternity-benefits-tech.
